Perfil de la empresa · Healthcare

Johnson & Johnson

JNJ · EE. UU.
Bolsa
EE. UU.
País / Región
USA
Fecha de salida a bolsa
24 de septiembre de 1944
Empleados
138.200
Sitio web
www.jnj.com
Precio actual
$265.95
En vivo · 27 de julio de 2026
Puntuación de crecimiento Baillie
48/100
Floja
Valor intrínseco · Rango en tres niveles Precio actual $265.95 En vivo · Por encima del techo optimista · crecimiento futuro sobregirado

Rango de valoración compuesto · conservador $120–$150 / razonable $150–$190 / optimista $190–$230. A $265.95, Por encima del techo optimista · crecimiento futuro sobregirado.

Al publicar $234.34 (25 de mayo de 2026)

Capitalización634,77 mil M US$
Ingresos (TTM)97,93 mil M US$
EBITDA34,84 mil M US$
Margen neto21,48 %
ROE26,42 %
PER (TTM)30,14
PER previsto22,27
PEG4,29
BPA8,74 US$
Rentabilidad por dividendo2,02 %
Rango de 52 semanas160,21 US$ – 269,43 US$
Precio objetivo de analistas270,59 US$
Recomendación de analistas3.8 / 5

Datos de EODHD, mostrados en la moneda de reporte; solo a título informativo, no constituye asesoramiento de inversión.

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.

Historia

Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey, with an IPO date of September 24, 1944. The company no longer includes its consumer health business, which was separated through the Kenvue spin-off, and is now organized around two segments: Innovative Medicine and MedTech. In 2026 the company achieved its 64th consecutive year of dividend increases.

Posición en el sector

Johnson & Johnson is a healthcare company in the Drug Manufacturers - General industry, operating worldwide with about 138,200 employees. In 2025 it reported total sales of roughly $94.2 billion, split between Innovative Medicine at about $60.4 billion and MedTech at about $33.8 billion. The company has disclosed that over 75% of its sales come from categories ranked first or second in global market share, and that it has 28 platforms each exceeding $1 billion in annual sales.

Aún no hay análisis sobre este valor en tu idioma.